Estos son algunos de los hallazgos de las investigaciones recientes que muestran qu puede suceder cuando dejas de tomar un GLP-1, adems de consejos de expertos sobre cmo mantener los beneficios para la salud que muchas personas obtienen de los medicamentos
All Day
Furthermore, CVOTs have documented the cardiovascular safety of the GLP-1 RA drug class in type 2 diabetes (Sattar et al., 2021)
Additionally, more investigation and scientific study is required to determine the correct protocols for best practices, safety, and optimal outcomes
Broader utility drives market dominance: GLP1s address not only diabetes and obesity, but also cardiovascular and other metabolic comorbidities, creating opportunities to position them as multicondition solutions
Clinical trials consistently demonstrate that patients using Ozempic achieve greater weight loss outcomes compared to those relying solely on lifestyle modifications or other weight-loss medications
